Hypercalcemia in a 56-year-old female

Laboratory Medicine

Volumn 39, Issue 1, 2008, Pages 23-28

  Pierce, Kristin A ^a   Willis, Monte S ^a   McCudden, Christopher R ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Adenoma; Hypercalcemia; Parathyroid; Primary hyperparathyroidism

Indexed keywords

EID: 62749197628     PISSN: 00075027     EISSN: None     Source Type: Journal    
DOI: 10.1309/YDQA3L57KQR4LTRT     Document Type: Article

References (38)

1. Sitges-Serra A, Bergenfelz A. Clinical update: Sporadic primary hyperparathyroidism. Lancet. 2007;370:468-470.
2. Silver J, Levi R. Cellular and molecular mechanisms of secondary hyperparathyroidism. Clin Nephrol. 2005;63:119-126.
3. Casez J, Pfammatter R, Nguyen Q, et al. Diagnostic approach to hypercalcemia: Relevance of parathyroid hormone and parathyroid hormonerelated protein measurements. Eur J Intern Med. 2001;12:344-349.
4. Rankin W, Grill V, Martin TJ. Parathyroid hormone-related protein and hypercalcemia. Cancer. 1997;80:1564-1571.
5. Terpos E, Dimopoulos MA. Myeloma bone disease: Pathophysiology and management. Ann Oncol. 2005;16:1223-1231.
6. Siris ES, Lyles KW, Singer FR, et al. Medical management of Paget's disease of bone: Indications for treatment and review of current therapies. J Bone Miner Res. 2006;21:94-98.
7. Stewart AF, Adler M, Byers CM, et al. Calcium homeostasis in immobilization: An example of resorptive hypercalciuria. N Engl J Med. 1982;306:1136-1140.
8. Adams JS. Vitamin D metabolite-mediated hypercalcemia. Endocrinol Metab Clin North Am. 1989;18:765-778.
9. Spiegel AM, Rudorfer MV, Marx SJ, et al. The effect of short term lithium administration on suppressibility of parathyroid hormone secretion by calcium in vivo. J Clin Endocrinol Metab. 1984;59:354-357.
10. Bartsch D, Nies C, Hasse C, et al. Clinical and surgical aspects of double adenoma in patients with primary hyperparathyroidism. Br J Surg. 1995;82:926-929.
11. Ruda JM, Hollenbeak CS, Stack BC Jr. A systematic review of the diagnosis and treatment of primary hyperparathyroidism from 1995 to 2003. Otolaryngol Head Neck Surg. 2005;132:359-372.
12. Bilezikian JP, Potts JT Jr, Fuleihan Gel H, et al. Summary statement from a workshop on asymptomatic primary hyperparathyroidism: A perspective for the 21st century. J Clin Endocrinol Metab. 2002;87:5353-5361.
13. Sitges-Serra A, Bergenfelz A. Clinical update: Sporadic primary hyperparathyroidism. Lancet. 2007;370(9586):468-470. Clinical update: Sporadic primary hyperparathyroidism 1474-1547X (Electronic).
14. Bergenfelz A, Kanngiesser V, Zielke A, et al. Conventional bilateral cervical exploration versus open minimally invasive parathyroidectomy under local anaesthesia for primary hyperparathyroidism. Br J Surg. 2005;92:190-197.
15. Bergenfelz A, Lindblom P, Tibblin S, et al. Unilateral versus bilateral neck exploration for primary hyperparathyroidism: A prospective randomized controlled trial. Ann Surg. 2002;236:543-551.
16. Russell CF, Dolan SJ, Laird JD. Randomized clinical trial comparing scandirected unilateral versus bilateral cervical exploration for primary hyperparathyroidism due to solitary adenoma. Br J Surg. 2006;93:418-421.
17. Sokoll LJ. Measurement of parathyroid hormone and application of parathyroid hormone in intraoperative monitoring. Clin Lab Med. 2004;24:199-216.
18. Gawande AA, Monchik JM, Abbruzzese TA, et al. Reassessment of parathyroid hormone monitoring during parathyroidectomy for primary hyperparathyroidism after 2 preoperative localization studies. Arch Surg. 2006;141:381-384.
19. Hortin GL, Carter AB. Intraoperative parathyroid hormone testing: Survey of testing program characteristics. Arch Pathol Lab Med. 2002;126:1045-1049.
20. Sokoll LJ, Wians FH Jr, Remaley AT. Rapid intraoperative immunoassay of parathyroid hormone and other hormones: A new paradigm for point-of-care testing. Clin Chem. 2004;50:1126-1135.
21. Johnson LR, Doherty G, Lairmore T, et al. Evaluation of the performance and clinical impact of a rapid intraoperative parathyroid hormone assay in conjunction with preoperative imaging and concise parathyroidectomy. Clin Chem. 2001;47:919-925.
22. Tisell LE, Hansson G, Lindberg S, et al. Hyperparathyroidism in persons treated with X-rays for tuberculous cervical adenitis. Cancer. 1977;40:846-854.
23. Beard CM, Heath H 3rd, O'Fallon WM, et al. Therapeutic radiation and hyperparathyroidism. A case-control study in Rochester, Minn. Arch Intern Med. 1989;149:1887-1890.
24. Schneider AB, Gierlowski TC, Shore-Freedman E, et al. Dose-response relationships for radiation-induced hyperparathyroidism. J Clin Endocrinol Metab. 1995;80:254-257.
25. Arnold A, Shattuck TM, Mallya SM, et al. Molecular pathogenesis of primary hyperparathyroidism. J Bone Miner Res. 2002;17:30-36.
26. Hendy GN. Molecular mechanisms of primary hyperparathyroidism. Rev Endocr Metab Disord. 2000;1:297-305.
27. Shattuck TM, Valimaki S, Obara T, et al. Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N Engl J Med. 2003;349:1722-1729.
28. Arnold A, Kim HG. Clonal loss of one chromosome 11 in a parathyroid adenoma. J Clin Endocrinol Metab. 1989;69:496-499.
29. Arnold A, Kim HG, Gaz RD, et al. Molecular cloning and chromosomal mapping of DNA rearranged with the parathyroid hormone gene in a parathyroid adenoma. J Clin Invest. 1989;83:2034-2040.
30. Hemmer S, Wasenius VM, Haglund C, et al. Deletion of 11q23 and cyclin D1 overexpression are frequent aberrations in parathyroid adenomas. Am J Pathol. 2001;158:1355-1362.
31. Hsi ED, Zukerberg LR, Yang WI, et al. Cyclin D1/PRAD1 expression in parathyroid adenomas: An immunohistochemical study. J Clin Endocrinol Metab. 1996;81:1736-1739.
32. Rosenberg CL, Kim HG, Shows TB, et al. Rearrangement and overexpression of D11S287E, a candidate oncogene on chromosome 11q13 in benign parathyroid tumors. Oncogene. 1991;6:449-453.
33. Vasef MA, Brynes RK, Sturm M, et al. Expression of cyclin D1 in parathyroid carcinomas, adenomas, and hyperplasias: A paraffin immunohistochemical study. Mod Pathol. 1999;12:412-416.
34. Agarwal SK, Kester MB, Debelenko LV, et al. Germline mutations of the MEN1 gene in familial multiple endocrine neoplasia type 1 and related states. Hum Mol Genet. 1997;6:1169-1175.
35. Friedman E, Sakaguchi K, Bale AE, et al. Clonality of parathyroid tumors in familial multiple endocrine neoplasia type 1. N Engl J Med. 1989;321:213-218.
36. Thakker RV, Bouloux P, Wooding C, et al. Association of parathyroid tumors in multiple endocrine neoplasia type 1 with loss of alleles on chromosome 11. N Engl J Med. 1989;321:218-224.
37. Björklund P, Akerstrom G, Westin G. Accumulation of nonphosphorylated beta-catenin and c-myc in primary and uremic secondary hyperparathyroid tumors. J Clin Endocrinol Metab. 2007;92:338-344.
38. Nakaoka D, Sugimoto T, Kobayashi T, et al. Prediction of bone mass change after parathyroidectomy in patients with primary hyperparathyroidism. J Clin Endocrinol Metab. 2000;85:1901-1907.